Friberg LE et al (2012) Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother 56(6):3032–3042

Article  PubMed  PubMed Central  Google Scholar 

Neely M et al (2010) Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 50(1):27–36

Article  PubMed  Google Scholar 

Walsh TJ et al (2004) Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 48(6):2166–2172

Article  PubMed  PubMed Central  Google Scholar 

Figueras JMVT et al (2021) Voriconazole use in children: therapeutic drug monitoring and control of inflammation as key points for optimal treatment. J Fungi (Basel) 7(6):456

Article  Google Scholar 

Hu L et al (2018) Therapeutic drug monitoring of voriconazole in children from a tertiary care center in China. Antimicrob Agents Chemother 62(12):e00955-18

Article  PubMed  PubMed Central  Google Scholar 

Taher KW et al (2024) Therapeutic drug monitoring of voriconazole in critically ill pediatric patients: a single-center retrospective study. Paediatr Drugs 26(2):197–203

Article  PubMed  Google Scholar 

Takesue Y et al (2022) Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Clin Ther 44(12):1604–1623

Article  PubMed  Google Scholar 

Kably B et al (2022) Antifungal drugs TDM: trends and update. Ther Drug Monit 44(1):166–197

Article  PubMed  Google Scholar 

Jelliffe R (2000) Goal-oriented, model-based drug regimens: setting individualized goals for each patient. Ther Drug Monit 22(3):325–329

Article  PubMed  Google Scholar 

Holford NH (1999) Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 48(1):9–13

Article  PubMed  PubMed Central  Google Scholar 

Hope WW et al (2013) Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob Agents Chemother 57(4):1888–1894

Article  PubMed  PubMed Central  Google Scholar 

Holford N (2018) Pharmacodynamic principles and target concentration intervention. Transl Clin Pharmacol 26(4):150–154

Article  PubMed  PubMed Central  Google Scholar 

Holford NH, Ma G, Metz D (2022) TDM is dead Long live TCI. Br J Clin Pharmacol 88(4):1406–1413

Article  PubMed  Google Scholar 

Alsultan A et al (2020) Clinical pharmacology applications in clinical drug development and clinical care: a focus on Saudi Arabia. Saudi Pharm J 28(10):1217–1227

Article  PubMed  PubMed Central  Google Scholar 

Tyson RJ et al (2020) Precision dosing priority criteria: drug, disease, and patient population variables. Front Pharmacol 11:420

Article  PubMed  PubMed Central  Google Scholar 

Kantasiripitak W et al (2020) Software tools for model-informed precision dosing: how well do they satisfy the needs? Front Pharmacol 11:620

Article  PubMed  PubMed Central  Google Scholar 

Tucker L et al (2015) Voriconazole monitoring in children with invasive fungal infections. J Pediatr Pharmacol Ther 20(1):17–23

PubMed  PubMed Central  Google Scholar 

Dolton MJ et al (2014) Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. J Antimicrob Chemother 69(6):1633–1641

Article  PubMed  Google Scholar 

Pascual A et al (2012) Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 55(3):381–390

Article  PubMed  Google Scholar 

Anderson BJ, Holford NH (2013) Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child 98(9):737–744

Article  PubMed  Google Scholar 

https://wfn.sourceforge.net/clinpharmacol/nextdose/medicines/voriconazole.htm. 2024 [cited 2024 9/15/2024]. Accessed 13 Sept 2024

Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9(4):503–512

Article  PubMed  Google Scholar 

Johansson AM et al (2014) Evaluation of bias, precision, robustness and runtime for estimation methods in NONMEM 7. J Pharmacokinet Pharmacodyn 41(3):223–238

Article  PubMed  Google Scholar 

Hara M et al (2017) Predictive performance of eleven pharmacokinetic models for propofol infusion in children for long-duration anaesthesia. Br J Anaesth 118(3):415–423

Article  PubMed  Google Scholar 

Cunio CB et al (2020) Towards precision dosing of vancomycin in critically ill patients: an evaluation of the predictive performance of pharmacometric models in ICU patients. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2020.07.005

Hanafin PO et al (2021) Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. CPT Pharmacometrics Syst Pharmacol 10(12):1525–1537

Article  PubMed  PubMed Central  Google Scholar 

Zhao CY et al (2016) External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol 81(5):891–907

Article  PubMed  PubMed Central  Google Scholar 

Lempers VJ et al (2019) Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. Med Mycol 57(8):937–943

Article  PubMed  Google Scholar 

Boast A et al (2016) Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre. J Antimicrob Chemother 71(7):2031–2036

Article  PubMed  Google Scholar 

Marsot A (2018) Pharmacokinetic variability in pediatrics and intensive care: toward a personalized dosing approach. J Pharm Pharm Sci 21(1):354–362

Article  PubMed  Google Scholar 

Goljan E et al (2022) Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population. PLoS ONE 17(1):e0263137

Article  PubMed  PubMed Central  Google Scholar 

Alkattan A et al (2021) The CYP2C19 genotypes and its effect on clopidogrel as an anti-platelet drug among the Arab population. Indian J Pharmacol 53(1):85–87

Article  PubMed  PubMed Central  Google Scholar 

Alsultan A et al (2023) Interethnic differences in drug response: projected impact of genetic variations in the Saudi population. Pharmacogenomics. https://doi.org/10.2217/pgs-2023-0105

Liu L et al (2017) Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China. Int J Antimicrob Agents 49(4):483–487

Article  PubMed  Google Scholar 

Teusink A et al (2016) Genotype-directed dosing leads to optimized voriconazole levels in pediatric patients receiving hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 22(3):482–486

Article  PubMed  Google Scholar